--- title: "CLSA Reaffirms Their Buy Rating on Zhuzhou CRRC Times Electric Co (ZHUZF)" type: "News" locale: "en" url: "https://longbridge.com/en/news/284470324.md" description: "CLSA analyst maintained a Buy rating on Zhuzhou CRRC Times Electric Co yesterday and set a price target of HK$43.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Zhuzhou CRRC Times Electric Co has an analyst consensus of Moderate Buy, with a price target consensus of HK$44.91." datetime: "2026-04-29T00:26:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284470324.md) - [en](https://longbridge.com/en/news/284470324.md) - [zh-HK](https://longbridge.com/zh-HK/news/284470324.md) --- # CLSA Reaffirms Their Buy Rating on Zhuzhou CRRC Times Electric Co (ZHUZF) CLSA analyst maintained a Buy rating on Zhuzhou CRRC Times Electric Co yesterday and set a price target of HK$43.00. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Zhuzhou CRRC Times Electric Co has an analyst consensus of Moderate Buy, with a price target consensus of HK$44.91. ### Related Stocks - [05477.HK](https://longbridge.com/en/quote/05477.HK.md) - [562960.CN](https://longbridge.com/en/quote/562960.CN.md) - [159611.CN](https://longbridge.com/en/quote/159611.CN.md) - [03898.HK](https://longbridge.com/en/quote/03898.HK.md) - [688187.CN](https://longbridge.com/en/quote/688187.CN.md) ## Related News & Research - [First Shanghai Securities Reaffirms Their Buy Rating on Zhuzhou CRRC Times Electric Co (ZHUZF)](https://longbridge.com/en/news/285490458.md) - [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md) - [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md) - [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md) - [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)